Finerenone improves outcomes in HFmrEF and HFpEF

IF 41.7 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Nature Reviews Cardiology Pub Date : 2024-09-19 DOI:10.1038/s41569-024-01087-x

Irene Fernández-Ruiz

引用次数: 0

Abstract

The non-steroidal mineralocorticoid receptor antagonist finerenone reduces the risk of adverse outcomes in patients with heart failure with mildly reduced ejection fraction or with preserved ejection fraction, according to findings presented at the ESC Congress 2024.

Abstract Image

查看原文本刊更多论文

非格列酮能改善高房颤mrEF和高房颤pEF的预后

根据在ESC 2024年大会上公布的研究结果，非甾体类矿物皮质激素受体拮抗剂非奈瑞酮可降低射血分数轻度降低或射血分数保留的心力衰竭患者出现不良后果的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Cardiology 医学-心血管系统

CiteScore

53.10

自引率

0.60%

发文量

143

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Cardiology aims to be the go-to source for reviews and commentaries in the scientific and clinical communities it serves. Focused on providing authoritative and accessible articles enriched with clear figures and tables, the journal strives to offer unparalleled service to authors, referees, and readers, maximizing the usefulness and impact of each publication. It covers a broad range of content types, including Research Highlights, Comments, News & Views, Reviews, Consensus Statements, and Perspectives, catering to practising cardiologists and cardiovascular research scientists. Authored by renowned clinicians, academics, and researchers, the content targets readers in the biological and medical sciences, ensuring accessibility across various disciplines. In-depth Reviews offer up-to-date information, while Consensus Statements provide evidence-based recommendations. Perspectives and News & Views present topical discussions and opinions, and the Research Highlights section filters primary research from cardiovascular and general medical journals. As part of the Nature Reviews portfolio, Nature Reviews Cardiology maintains high standards and a wide reach.